tiprankstipranks
Trending News
More News >

BrainsWay Announces Positive Results from Accelerated Deep TMS Study for Depression

Story Highlights
  • BrainsWay’s accelerated Deep TMS protocol shows comparable efficacy to standard treatment.
  • The study indicates fewer clinic visits and faster remission for depression patients.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
BrainsWay Announces Positive Results from Accelerated Deep TMS Study for Depression

Confident Investing Starts Here:

Brainsway ( (BWAY) ) has provided an announcement.

On June 11, 2025, BrainsWay Ltd. announced positive preliminary results from a multicenter, randomized controlled trial of its accelerated Deep TMS protocol for major depressive disorder (MDD). The study, involving 104 patients across eight sites, demonstrated that the accelerated protocol, which requires fewer clinic visits, achieved comparable efficacy to the standard protocol in reducing depression symptoms. The accelerated treatment was well-tolerated, with no serious adverse events, and showed a quicker median time to remission. This advancement could significantly impact patient accessibility and treatment logistics in mental health care.

The most recent analyst rating on (BWAY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.

Spark’s Take on BWAY Stock

According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.

Brainsway’s strong financial performance, characterized by revenue growth and balance sheet robustness, is the primary driver of the stock’s favorable score. The technical analysis supports a positive momentum, though caution is advised due to high valuation metrics. The positive earnings call further reinforces the company’s potential for growth, albeit with some risks from increased expenses and geopolitical factors.

To see Spark’s full report on BWAY stock, click here.

More about Brainsway

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to Deep TMS.

Average Trading Volume: 36,030

Technical Sentiment Signal: Buy

Current Market Cap: $220.7M

See more data about BWAY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1